USPTO serial 98851818
AP3
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- STIGLITZ, SUSAN R
- Law office
- TMEG LAW OFFICE 109
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AP3?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sara M. Bauer
Sara M. Bauer Womble Bond Dickinson (US) LLP470 Atlantic Ave; Suite 600Independence WharfBoston, MA 02210Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | scientific research; medical research; proteomics and biomarker discovery services, namely, medical testing services and information in the field of disease classification; scientific research and development in the fields of pharmaceuticals, therapeutics, and drug formulation and delivery; scientific research and development in the fields of proteomics and biomarker discovery; consultancy services in the field of pharmaceutical research and development services; consultancy services in the fields of medical and scientific research concerning proteomics and biomarker discovery; pharmaceutical research services related to prediction of drug treatment efficacy; medical research services related to prediction of drug treatment efficacy; conducting scientific studies in the fields of proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification; proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder identification; providing information in the field of medical, scientific and pharmaceutical research about proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, precision medicine clinical trials based on responder indication services; scientific and technological research and consultation services, namely, in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, pharmacodynamic biomarkers, drug repurposing, patient responder identification, indication finding, and rational drug design; drug discovery services in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, and rational drug design through optimal pathway effects in intact cells; consultancy in the field of pharmaceutical research and development services in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers, drug repurposing, indication finding, and rational drug design through pathway-based SAR | ACTIVE | — |
| 044 | Medical services; medical testing for diagnosis or treatment purposes; medical diagnostic testing, monitoring, and reporting services; providing medical information, consultancy and advisory services; individual medical counseling services provided to patients; providing a website featuring information in the field of precision medicine; providing medical information to medical professionals in the form of reports in the field of precision medicine; proteomics and biomarker discovery services, namely, medical diagnostic services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 25, 2026 | MAB1 | ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT | — |
| Mar 25, 2026 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Mar 24, 2026 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Feb 6, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 28, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 28, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 28, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 7, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 7, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 7, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 9, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2025 | LOPE | LETTER OF PROTEST EVIDENCE REVIEWED - ACTION TAKEN | — |
| Jun 8, 2025 | LOPT | LETTER OF PROTEST EVIDENCE FORWARDED | — |
| May 9, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 9, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 9, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 9, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 13, 2024 | NWAP | NEW APPLICATION ENTERED | — |